Stockreport

Nkarta rises on FDA agreement for amended trial protocol [Seeking Alpha]

Nkarta, Inc.  (NKTX) 
PDF FDA to change the protocol of a clinical program that allows outpatient dosing of its lead asset, NKX019. The ongoing Ntrust-1 and Ntrust-2 clinical trials are designe [Read more]